InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the detailed record of transactions filed by Lydon Nicholas, 董事. Director active across 1 company, notably Blueprint Medicines Corp. In total, 5 reports have been logged. History available since 2 June 2021. The latest transaction was disclosed on 12 June 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Lydon Nicholas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
2,242 股0Common StockSEC:0001415889-24-016982:0
2,600 股0Common StockSEC:0001415889-23-010257:0
2,600 股0Common StockSEC:0001415889-22-007132:0
10,909 股@ US$19.53100.0% 占其流量Common StockSEC:0001415889-22-005656:0
2,250 股0Common StockSEC:0001179110-21-006414:0
5 条申报中的 5 条
About Lydon Nicholas
Nicholas Lydon is a Board Member at Blueprint Medicines Corp. He plays a key role in the governance of the company, contributing to strategic decision-making and overseeing activities.
